SCOTTSDALE, Ariz., Aug. 16 /PRNewswire-FirstCall/ -- IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO) today released a letter to shareholders from Chairman and CEO Michael K. Wilhelm. The purpose of the letter is to provide an update to its shareholders on its subsidiary ImmuneRegen BioSciences' past year of progress in the infectious disease and disaster preparedness sectors. ImmuneRegen today has also filed a Form 8-K containing the shareholder letter with the Securities and Exchange Commission. The Form 8-K will be available on ImmuneRegen's website at http://www.immuneregen.com. The text of the letter is contained below:
The previous year has been a noteworthy one for ImmuneRegen BioSciences. Our scientific and business activities have accelerated, and the company has recently announced several noteworthy achievements and events such as acquisition of study results, formation of collaborative and co-development relationships as well as presentations at conferences and to the FDA and NIH. The response by these agencies of the Department of Health and Human Services remains quite positive as we continue to deliver additional data in multiple areas of both scientific and product development interest and having potential commercial appeal.
Current research programs include microbiological infection such as
anthrax bacillus, and influenza (including avian influenza vaccine
adjuvancy), in addition to radiation exposure (to both lethal and
sub-lethal/therapeutic doses). Results of our influenza studies indicate
that Viprovex(R) lowers viral load 90-99% in nose and lungs of treated
animals, as well as lowers the magnitude of the virus-induced decreases in
body weight and temperature. These studies also indicate that Viprovex
decreases the inflammatory reaction in the lungs of infected animals, even
in the presence of Roche's influenza treatment and preventative,
|SOURCE ImmuneRegen BioSciences, Inc.|
Copyright©2007 PR Newswire.